Context Therapeutics Inc. is a women's oncology company developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers. Context Therapeutics Inc. is headquartered in Philadelphia, PA.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-26.73M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.61 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -29.78% |
| Return on Assets (Trailing 12 Months) | -29.08% |
| Current Ratio (Most Recent Fiscal Quarter) | 48.81 |
| Quick Ratio (Most Recent Fiscal Quarter) | 48.81 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $1.01 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.05 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.46 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.31 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 89.70M |
| Free Float | 87.19M |
| Market Capitalization | $55.37M |
| Average Volume (Last 20 Days) | 0.11M |
| Beta (Past 60 Months) | 2.11 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 2.80% |
| Percentage Held By Institutions (Latest 13F Reports) | 14.03% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |